



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Urtoxazumab

Cat. No.:	HY-P99532
CAS No.:	502496-16-4
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Urtoxazumab (TMA-15) is a humanized monoclonal antibody against Shiga toxin (Stx) 2 ^[1] .								
In Vivo	<p>Urtoxazumab (TMA-15) (0.25-2.5 mg/kg; i.v.; once) ameliorates the lethal challenge in a time- and dose- dependent manner in B2F1-infected mice^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>5-week-old male DBA/2J mice, STEC B2F1-infection model^[1]</td> </tr> <tr> <td>Dosage:</td> <td>0.25, 0.5, 1.0, 2.0 and 2.5 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intravenous administration, 1 h before and 12, 24, and 48 h after infection</td> </tr> <tr> <td>Result:</td> <td>Pretreatment completely protected the infected mice from death, the efficacy of the low dose (0.25 mg/kg) was partial when administered at 12 and 24 h after infection, but the efficacy of the high dose (2.5 mg/kg) was still complete. Prevented death from B2F1 infection in all 20 animals at 1.0 and 2.0 mg/kg 24 h after infection.</td> </tr> </table>	Animal Model:	5-week-old male DBA/2J mice, STEC B2F1-infection model ^[1]	Dosage:	0.25, 0.5, 1.0, 2.0 and 2.5 mg/kg	Administration:	Intravenous administration, 1 h before and 12, 24, and 48 h after infection	Result:	Pretreatment completely protected the infected mice from death, the efficacy of the low dose (0.25 mg/kg) was partial when administered at 12 and 24 h after infection, but the efficacy of the high dose (2.5 mg/kg) was still complete. Prevented death from B2F1 infection in all 20 animals at 1.0 and 2.0 mg/kg 24 h after infection.
Animal Model:	5-week-old male DBA/2J mice, STEC B2F1-infection model ^[1]								
Dosage:	0.25, 0.5, 1.0, 2.0 and 2.5 mg/kg								
Administration:	Intravenous administration, 1 h before and 12, 24, and 48 h after infection								
Result:	Pretreatment completely protected the infected mice from death, the efficacy of the low dose (0.25 mg/kg) was partial when administered at 12 and 24 h after infection, but the efficacy of the high dose (2.5 mg/kg) was still complete. Prevented death from B2F1 infection in all 20 animals at 1.0 and 2.0 mg/kg 24 h after infection.								

REFERENCES

[1]. Yamagami S, et al. Efficacy of postinfection treatment with anti-Shiga toxin (Stx) 2 humanized monoclonal antibody TMA-15 in mice lethally challenged with Stx-producing Escherichia coli. J Infect Dis. 2001 Sep 15;184(6):738-42.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA